Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis译:姚佳思 校:曹文东本文来自罕见病信息网团队。欢迎转发分享;媒体、网站等平台如需转载,须注明来源。如有其他合作需求,请发送邮件至:info@cord.org.cn。
Phase 1 studies of PLN-74809 in healthy volunteers have demonstrated good oral bioavailability and tolerability with a t1/2 supportive of once daily dosing.Inhibition of αVβ6-mediated TGF-β activation in the lung by can be detected through measurement of SMAD phosphorylation in alveolar ...
之前在关注名单里排第二 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholan…
Phase 2 drug target engagement study of PLN-74809 in patients with idiopathic pulmonary fibrosis using a novel αvβ6 cystine knot PET imaging tracer2236 Introduction: Molecular imaging holds great potential to advance our understanding of pulmonary fibrosis and accelerate the development of novel ...
INTEGRIS-PSC phase 2a study: evaluating the safety, tolerability, and pharmacokinetics of bexotegrast (PLN-74809) in participants with primary sclerosing cholangitisdoi:10.1016/S0168-8278(23)01037-1Gideon HirschfieldPalak TrivediCynthia LevyChristoph Schramm...